AC-CUTE: An Open-Label Study to Evaluate Progression of Structural Joint Damage and Inflammation in Subjects with Moderate to Severe Rheumatoid Arthritis

Table 2

Changes in TSS and components and RAMRIS feature scores from baseline to Week 24.

	FAS	SC-TCZM	SC-TCZC
TSS (X-ray)
Mean (SD)	0.46 (1.29)	0.65 (1.30)	0.36 (1.30)
	0.83	0.93	0.77
Erosion (X-ray)
Mean (SD)	0.14 (0.46)	0.16 (0.40)	0.12 (0.49)
	0.92	0.99	0.89
JSN (X-ray)
Mean (SD)	0.32 (0.94)	0.49 (1.0)	0.24 (0.91)
	0.89	0.97	0.83
Erosion (MRI)
Mean (SD)	0.9 (1.66)	0.79 (2.0)	0.96 (1.5)
	0.51	0.69	0.55
Cartilage loss (MRI)
Mean (SD)	0.12 (0.59)	0.09 (0.90)	0.14 (0.35)
	0.93	0.97	0.93
Synovitis (MRI)
Mean (SD)	−1.7 (2.67)	−1.6 (2.5)	−1.8 (2.8)
	0.04	0.37	0.04
Osteitis (MRI)
Mean (SD)	−4.0 (9.58)	−2.9 (7.9)	−4.6 (10.4)
	0.21	0.55	0.26

rank-sum test of the hypothesis of no change from baseline at Week 24. Testing change in each subgroup separately; FAS, full analysis set; TSS, Genant-modified total Sharp Score; SC-TCZC, subcutaneous tocilizumab combination therapy subgroup (including MTX); SC-TCZM, subcutaneous tocilizumab monotherapy subgroup (including DMARD(s) but excluding MTX).